Active
Phase 2 study of everolimus in combination with bevacizumab in patients with sporadic and neurofibromatosis type 1 related refractory malignant peripheral nerve sheath tumors
Type of Sarcoma:
malignant peripheral nerve sheath tumor (MPNST) either sporadic or NF1 associated
Drug:
bevacizumab and everolimus
Accrual Status:
Open, Not Accruing
Overall Study Principal Investigator:
Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute